Display Settings:

Format

Send to:

Choose Destination
Expert Rev Respir Med. 2010 Oct;4(5):631-45. doi: 10.1586/ers.10.64.

Lung cancer therapeutics that target signaling pathways: an update.

Author information

  • 1Thoracic Oncology Program, Department of Surgery, University of California, San Francisco, CA 94115, USA.

Abstract

Claiming more than 150,000 lives each year, lung cancer is the deadliest cancer in the USA. First-line treatments in lung cancer include surgical resection and chemotherapy, the latter of which offers only modest survival benefits at the expense of often severe and debilitating side effects. Recent advances in elucidating the molecular biology of lung carcinogenesis have elucidated novel drug targets, and treatments are rapidly evolving into specialized agents that hone in on specific aspects of the disease. Of particular interest is blocking tumor growth by targeting the physiological processes surrounding angiogenesis, pro-tumorigenic growth factor activation, anti-apoptotic cascades and other cancer-promoting signal transduction events. This article looks at several areas of interest to lung cancer therapeutics and considers the current state of affairs surrounding the development of these therapies.

PMID:
20923341
[PubMed - indexed for MEDLINE]
PMCID:
PMC3031455
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk